Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study
The addition of adjuvant immunotherapy to neoadjuvant chemoimmunotherapy may not be necessary in patients with resectable stage III NSCLC. Three cycles of neoadjuvant immunotherapy appear to be an appropriate treatment regimen for neoadjuvant chemoimmunotherapy.
Authors
- Jingjing Yan (ORCID: https://orcid.org/0000-0002-3581-7665)
- Cuimeng Tian (ORCID: https://orcid.org/0000-0002-8538-241X)
- Feng Guo (ORCID: https://orcid.org/0000-0002-0478-7491)
- Zhaoxin Chen (ORCID: https://orcid.org/0000-0002-7616-9836)
- Hui Wang (ORCID: https://orcid.org/0000-0001-9972-2019)
- Guohui Yi (ORCID: https://orcid.org/0000-0003-2343-7144)
- Xingyu Du
- Song Guan
Institutions
- Hospital of Hebei Province (CN)
- Beijing Chest Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-07-21
- DOI
- https://doi.org/10.1007/s00262-025-04130-z
- Citations
- 1
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52